These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
233 related articles for article (PubMed ID: 36050142)
1. The evolving regulatory landscape in regenerative medicine. Beetler DJ; Di Florio DN; Law EW; Groen CM; Windebank AJ; Peterson QP; Fairweather D Mol Aspects Med; 2023 Jun; 91():101138. PubMed ID: 36050142 [TBL] [Abstract][Full Text] [Related]
2. From bench to FDA to bedside: US regulatory trends for new stem cell therapies. Knoepfler PS Adv Drug Deliv Rev; 2015 Mar; 82-83():192-6. PubMed ID: 25489841 [TBL] [Abstract][Full Text] [Related]
3. The Future of Regenerative Medicine: Cell Therapy Using Pluripotent Stem Cells and Acellular Therapies Based on Extracellular Vesicles. Jarrige M; Frank E; Herardot E; Martineau S; Darle A; Benabides M; Domingues S; Chose O; Habeler W; Lorant J; Baldeschi C; Martinat C; Monville C; Morizur L; Ben M'Barek K Cells; 2021 Jan; 10(2):. PubMed ID: 33513719 [TBL] [Abstract][Full Text] [Related]
4. Expediting Drug Development: FDA's New Regenerative Medicine Advanced Therapy Designation. Vaggelas A; Seimetz D Ther Innov Regul Sci; 2019 May; 53(3):364-373. PubMed ID: 29895180 [TBL] [Abstract][Full Text] [Related]
5. US FDA outreach to the regenerative medicine community: challenges and opportunities. Whittlesey KJ; Witten C Regen Med; 2012 Jul; 7(4):595-603. PubMed ID: 22817631 [TBL] [Abstract][Full Text] [Related]
6. Concise Review: The U.S. Food and Drug Administration and Regenerative Medicine. Witten CM; McFarland RD; Simek SL Stem Cells Transl Med; 2015 Dec; 4(12):1495-9. PubMed ID: 26494784 [TBL] [Abstract][Full Text] [Related]
7. The therapeutic and commercial landscape of stem cell vesicles in regenerative dermatology. Davies OG; Williams S; Goldie K J Control Release; 2023 Jan; 353():1096-1106. PubMed ID: 36535543 [TBL] [Abstract][Full Text] [Related]
8. The Food and Drug Administration, regenerative sciences, and the regulation of autologous stem cell therapies. von Tigerstrom B Food Drug Law J; 2011; 66(4):479-506, i. PubMed ID: 24505826 [TBL] [Abstract][Full Text] [Related]
9. Regenerative Medicine Therapies for Rare Diseases. Lapteva L; Vatsan R; Purohit-Sheth T Transl Sci Rare Dis; 2018 Dec; 3(3-4):121-132. PubMed ID: 30613470 [TBL] [Abstract][Full Text] [Related]
10. Engineering Extracellular Vesicles as Nanotherapeutics for Regenerative Medicine. Ramasubramanian L; Kumar P; Wang A Biomolecules; 2019 Dec; 10(1):. PubMed ID: 31905611 [TBL] [Abstract][Full Text] [Related]
11. Stem Cells-Derived Extracellular Vesicles: Potential Therapeutics for Wound Healing in Chronic Inflammatory Skin Diseases. Manchon E; Hirt N; Bouaziz JD; Jabrane-Ferrat N; Al-Daccak R Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33808520 [TBL] [Abstract][Full Text] [Related]
12. Stem cell- derived extracellular vesicles as new tools in regenerative medicine - Immunomodulatory role and future perspectives. Karnas E; Dudek P; Zuba-Surma EK Front Immunol; 2023; 14():1120175. PubMed ID: 36761725 [TBL] [Abstract][Full Text] [Related]
13. Regulation of Regenerative Medicine Products. Gee AP Adv Exp Med Biol; 2018; 1098():189-198. PubMed ID: 30238372 [TBL] [Abstract][Full Text] [Related]
14. Cultivating regenerative medicine innovation in China. McMahon DS; Thorsteinsdóttir H; Singer PA; Daar AS Regen Med; 2010 Jan; 5(1):35-44. PubMed ID: 20055687 [TBL] [Abstract][Full Text] [Related]
15. Uncovering the gray zone: mapping the global landscape of direct-to-consumer businesses offering interventions based on secretomes, extracellular vesicles, and exosomes. Asadpour A; Yahaya BH; Bicknell K; Cottrell GS; Widera D Stem Cell Res Ther; 2023 May; 14(1):111. PubMed ID: 37138298 [TBL] [Abstract][Full Text] [Related]
16. Bone Marrow Concentrate (BMC) Therapy in Musculoskeletal Disorders: Evidence-Based Policy Position Statement of American Society of Interventional Pain Physicians (ASIPP). Manchikanti L; Centeno CJ; Atluri S; Albers SL; Shapiro S; Malanga GA; Abd-Elsayed A; Jerome M; Hirsch JA; Kaye AD; Aydin SM; Beall D; Buford D; Borg-Stein J; Buenaventura RM; Cabaret JA; Calodney AK; Candido KD; Cartier C; Latchaw R; Diwan S; Dodson E; Fausel Z; Fredericson M; Gharibo CG; Gupta M; Kaye AM; Knezevic NN; Kosanovic R; Lucas M; Manchikanti MV; Mason RA; Mautner K; Murala S; Navani A; Pampati V; Pastoriza S; Pasupuleti R; Philip C; Sanapati MR; Sand T; Shah RV; Soin A; Stemper I; Wargo BW; Hernigou P Pain Physician; 2020 Mar; 23(2):E85-E131. PubMed ID: 32214287 [TBL] [Abstract][Full Text] [Related]
17. FDA and NIST collaboration on standards development activities supporting innovation and translation of regenerative medicine products. Arcidiacono JA; Bauer SR; Kaplan DS; Allocca CM; Sarkar S; Lin-Gibson S Cytotherapy; 2018 Jun; 20(6):779-784. PubMed ID: 29784433 [TBL] [Abstract][Full Text] [Related]
18. Acellular approaches for regenerative medicine: on the verge of clinical trials with extracellular membrane vesicles? Fuster-Matanzo A; Gessler F; Leonardi T; Iraci N; Pluchino S Stem Cell Res Ther; 2015 Dec; 6():227. PubMed ID: 26631254 [TBL] [Abstract][Full Text] [Related]
19. Current status and perspectives on stem cell-based therapies undergoing clinical trials for regenerative medicine: case studies. Ratcliffe E; Glen KE; Naing MW; Williams DJ Br Med Bull; 2013; 108():73-94. PubMed ID: 24200742 [TBL] [Abstract][Full Text] [Related]
20. Current and emerging global themes in the bioethics of regenerative medicine: the tangled web of stem cell translation. Chan S Regen Med; 2017 Oct; 12(7):839-851. PubMed ID: 29119870 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]